• metastatic/advanced RCC (mRCC) - 1st line (L1) 11
• mRCC - L1 - PDL1 negative 1
• mRCC - L1 - PDL1 positive 4

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab
• avelumab based treatment
• avelumab plus axitinib

• versus all
• vs VEGF(R) inhibitor
• vs sunitinib

  All patients metastasis (liver ) previous nephrectomy (no) previous nephrectomy (yes) Risk favorable (IMDC) Risk favorable (MSKCC) Risk intermediate (IMDC) Risk intermediate (MSKCC) Risk poor (IMDC) Risk poor (MSKCC)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mRCC - L1 - PDL1 positive, atezolizumab plus bevacizumab vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;